NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype

Affiliations

• ¹ Department of Cellular Pathology, North Bristol NHS Trust, Bristol, United Kingdom; Harvard Medical School, Boston, MA, United States; Department of Pathology, Beth Israel Deaconess Medical Center, MA, United States. Electronic address: maximiliano.ramiadecap@nbt.nhs.uk.
• ² Harvard Medical School, Boston, MA, United States; Department of Pathology, Beth Israel Deaconess Medical Center, MA, United States.
• ³ Harvard Medical School, Boston, MA, United States; Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States.
• ⁴ Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States.
• ⁵ Department of Pathology, Weill Cornell Medical College, New York, NY, United States.
• ⁶ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
• ⁷ Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
• ⁸ Department of Pathology, Yale School of Medicine, New Haven, CT, United States.
• ⁹ Department of Pathology, Oregon Health & Science University, Portland, OR, United States.
• ¹⁰ Department of Pathology, Cleveland Clinic, Cleveland, OH, United States.
• ¹¹ Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
• ¹² Department of Pathology, Stanford University Medical Center, Palo Alto, CA, United States.
• ¹³ Department of Pathology, University of Chicago, Chicago, IL, United States.
• ¹⁴ Harvard Medical School, Boston, MA, United States; Department of Pathology, Massachusetts General Hospital, Boston, MA, United States.